# Ask about atomoxetine as an adult

Published by Pawel Jozefiak. [About this project](https://adhd100.jock.pl/about/), [How we check sources](https://adhd100.jock.pl/methodology/)

- Canonical: https://adhd100.jock.pl/discuss-atomoxetine-adult/
- Language: en
- First published: 2026-09-29
- Evidence checked: 2026-09-29, using AI-assisted source verification
- Clinical review: Not clinically reviewed
- Number 7 of 100 in the list: https://adhd100.jock.pl/#discuss-atomoxetine-adult

A nonstimulant with solid evidence behind it, for when stimulants don't suit you or haven't helped enough.

**The number:** Adults: small improvement in self-rated symptoms vs placebo over about 12 weeks (SMD 0.368) ([BMJ / Gosling et al., 2025](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv))

## The evidence

- How sure: Certainty of evidence: High certainty. Measured in people with ADHD.
- See this comparison on the evidence map: https://adhd100.jock.pl/evidence/#r-atomoxetine-adult-core-adhd-symptoms-self-rated-short
- Evidence grade: A. Grade A: moderate or high certainty evidence in people with ADHD, or an explicit ADHD guideline recommendation.
- Basis: EBI re-estimation: 7 trials, 1734 adults; high certainty applies specifically to short term self-ratings; NICE NG87 1.7.15
- Outcome: self-rated core ADHD symptom improvement in adults
- Comparison: vs placebo
- Benefit: 80/100. The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you.

## Why it matters

Atomoxetine is a nonstimulant medicine that affects noradrenaline signalling. EBI found a 0.368 SMD improvement in adults' self-rated symptoms versus placebo, with high certainty, but clinician-rated evidence was very low certainty. These findings concern about 12 weeks or trial endpoint, and do not establish long term benefit. NICE recommends it for adults who cannot tolerate, or have not been helped by, lisdexamfetamine and methylphenidate; more participants withdrew because of adverse effects than with placebo.

## How to do it

1. Ask whether a nonstimulant makes sense given your previous treatment and medical history.
2. Bring a short account of what stimulants did for you, the side effects, or why they may not suit you.
3. Ask how long the clinician expects it to take before you can judge whether it helps.
4. Talk through possible unwanted effects and set up a review plan.

## Talk to a clinician first

A clinician should decide whether it suits you, check interactions and plan monitoring. This adult estimate cannot be assumed to apply to children or to every outcome.

## Putting it into practice

### Start now

- 1 minute: Type the one question about nonstimulant treatment you most want answered.
- 5 minutes: List what you want from an alternative and what made previous treatment hard.
- 15 minutes: Write your questions about timing, side effects and the review appointment.

### What it looks like

- Ask: 'What would count as enough benefit, and when would we review it?'
- Bring up your concerns about previous medicines, including effects that felt awkward to mention.

### Common mistakes

- Nonstimulant does not mean free of side effects. Ask how you'll be monitored.
- Self-ratings and clinician ratings got different certainty ratings. Talk about the benefits that matter in your own life.

### A structured start

**Explore a nonstimulant option**

1. Review previous treatment and current needs.
2. Ask about suitability and realistic expectations.
3. Agree a clinician-led monitoring and review plan.

### Trusted how-to guides

- [ADHD in adults](https://www.nhs.uk/conditions/adhd-adults/), NHS
- [Tips for Talking With a Health Care Provider About Your Mental Health](https://www.nimh.nih.gov/health/publications/tips-for-talking-with-your-health-care-provider), NIMH

## Sources

- [EBI-ADHD: companion data to Gosling et al., BMJ 2025, commit 86eff22a9ffb](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv), BMJ / Gosling et al., 2025 (Tier 1 guideline)
- [Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making](https://pmc.ncbi.nlm.nih.gov/articles/PMC12651917/), BMJ, 2025 (Tier 1 guideline)
- [Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations), NICE, 2019 (Tier 1 guideline)

---

General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician.

Report an error: meet@jock.pl

Reuse: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/